BR100 Decreased By (-0.32%)
BR30 Decreased By (-0.61%)
KSE100 Decreased By (-0.19%)
KSE30 Decreased By (-0.14%)
AGHA 6.61 Decreased By ▼ -0.06 (-0.9%)
BECO 4.38 Increased By ▲ 0.03 (0.69%)
BML 55.25 Decreased By ▼ -0.92 (-1.64%)
BOP 29.93 Decreased By ▼ -0.19 (-0.63%)
CNERGY 12.70 Decreased By ▼ -0.28 (-2.16%)
CSIL 5.23 Decreased By ▼ -0.08 (-1.51%)
FCCL 51.60 Decreased By ▼ -0.05 (-0.1%)
FFL 14.43 Decreased By ▼ -0.06 (-0.41%)
FNEL 1.21 No Change ▼ 0.00 (0%)
KEL 6.00 Decreased By ▼ -0.06 (-0.99%)
KOSM 5.42 Decreased By ▼ -0.42 (-7.19%)
LOTCHEM 26.07 Decreased By ▼ -0.10 (-0.38%)
MLCF 91.05 Decreased By ▼ -0.18 (-0.2%)
NBP 161.50 Decreased By ▼ -2.69 (-1.64%)
NCPL 52.37 Decreased By ▼ -0.81 (-1.52%)
NPL 57.97 Decreased By ▼ -1.15 (-1.95%)
OGDC 314.95 Increased By ▲ 1.56 (0.5%)
PACE 9.80 Increased By ▲ 0.03 (0.31%)
PAEL 34.95 Decreased By ▼ -0.29 (-0.82%)
PIBTL 14.27 Decreased By ▼ -0.44 (-2.99%)
PPL 219.70 Decreased By ▼ -1.66 (-0.75%)
PRL 89.78 Decreased By ▼ -1.44 (-1.58%)
PTC 59.30 Increased By ▲ 0.11 (0.19%)
SSGC 23.19 Decreased By ▼ -0.11 (-0.47%)
TBL 8.70 Decreased By ▼ -0.05 (-0.57%)
TELE 7.45 Decreased By ▼ -0.16 (-2.1%)
TPL 21.18 Decreased By ▼ -0.85 (-3.86%)
TPLP 12.17 Decreased By ▼ -0.39 (-3.11%)
TREET 21.50 Decreased By ▼ -0.23 (-1.06%)
TRG 54.98 Decreased By ▼ -0.81 (-1.45%)

The Competition Commission of Pakistan (CCP) has approved the acquisition of a certain shareholding in Route2Health (Private) Limited by the UAE-based AZT Foundation, the regulator said on Friday.

According to the CCP, the shares will be acquired from Tausif Ahmad Khan, Zainub Abbas, and Javaid Hussain under a Share Purchase Agreement.

AZT Foundation was established to hold and manage assets on behalf of the sellers. Route2Health, a Pakistan-based company, operates in the manufacturing, marketing, and distribution of nutraceuticals and health supplements.

CCP clears acquisition of shareholding in Heavy Electrical Complex

The CCP said it carried out a detailed competitive assessment and identified the relevant product market as “nutraceutical and herbal supplements.” It noted that the deal qualified as a conglomerate merger since no horizontal or vertical overlaps exist between the buyer and the target company.

The Commission concluded that the acquisition would not create or strengthen a dominant position in the relevant market and cleared the transaction under Section 11 of the Competition Act, 2010.

Comments

Comments are closed for this article.